NASDAQ: SHOTSafety Shot Inc Stock
$0.52+0.02 (+4%)
Updated Apr 30, 2025
SHOT Price
$0.52
Fair Value Price
N/A
Market Cap
$38.64M
52 Week Low
$0.34
52 Week High
$1.77
P/E
-0.57x
P/B
-17.78x
P/S
55.84x
PEG
N/A
Dividend Yield
N/A
Revenue
$701.97k
Earnings
-$49.41M
Gross Margin
-348.4%
Operating Margin
-7,013.68%
Profit Margin
-7,365.4%
Debt to Equity
-4.38
Operating Cash Flow
-$18M
Beta
0.89
Next Earnings
May 13, 2025
Ex-Dividend
N/A
Next Dividend
N/A
SHOT Overview
Jupiter Wellness, Inc. develops cannabidiol (CBD) based medical therapeutics and wellness products. It also manufactures consumer products such as CBD-infused sunscreen under the CaniSun brand, CBD-infused skin care lotion under the CaniSkin brand, and products for dermatological treatment of pain and inflammation under the CaniDermRX brand. Jupiter Wellness was incorporated in 2018 and is headquartered in Jupiter, FL.
Zen Rating
Our proven quant model uses 115 proprietary factors, including AI, to determine SHOT's potential to beat the market
DSell
- Stocks with a Zen Rating of Sell (D) had an average loss of -4.50% per year. Learn More
Zen Rating Component Grades
F
Zen Rating uses advanced AI algorithms that detect subtle patterns in market data; it anticipates future trends that point to superior stock price results.
Industry: Beverage
Industry Rating
B
SHOT
Ranked#15 of 16
Ranked#15 of 16
Top Ranked Stocks in Industry
| Name / Ticker | Price | Zen Rating |
|---|---|---|
| $25.90 | A | |
| $1,355.81 | A | |
| $33.05 | B |
Be the first to know about important SHOT news, forecast changes, insider trades & much more!
SHOT News
Overview
Due Diligence Score
–
Industry Average (36)
You've viewed Due Diligence Score for 10/10 free stocks. Upgrade to Premium to see how SHOT scored across 33 valuation, financial, forecast, performance, and dividend due diligence checks.
Due Diligence Checks
SHOT is unprofitable, so we are unable to calculate its intrinsic value according to an updated version of Benjamin Graham's Formula from "The Intelligent Investor"
Below Benjamin Graham Formula Value Valuation
SHOT is unprofitable, so we are unable to assess its PEG ratio
PEG Value Valuation
SHOT's cash and short-term investments... subscribe to Premium to read more.
Interest Coverage Financials
There are 30 more SHOT due diligence checks available for Premium users.
Valuation
SHOT fair value
Fair Value of SHOT stock based on Discounted Cash Flow (DCF)
Price
$0.52
Fair Value
-$0.38
Undervalued by
237.35%
SHOT is unprofitable, so we... subscribe to Premium to read more.
Below Benjamin Graham Formula Value Valuation
SHOT price to earnings (PE)
For valuing profitable companies with steady earnings
Company
-0.57x
Industry
18.96x
Market
29.18x
SHOT price to book (PB)
For valuing companies that are loss-making or have lots of physical asset
Company
-17.78x
Industry
7.3x
SHOT's financial health
Profit margin
Revenue
$182.2k
Net Income
-$13.5M
Profit Margin
-8,686.7%
SHOT's cash and short-term investments... subscribe to Premium to read more.
Interest Coverage Financials
SHOT's profit margin has increased... subscribe to Premium to read more.
Profit Margin Growth Financials
Assets to liabilities
Assets
$7.3M
Liabilities
$9.5M
Debt to equity
-4.38
SHOT's short-term liabilities ($9.40M) exceed... subscribe to Premium to read more.
Short-term Liabilities Financials
SHOT's short-term assets ($2.58M) exceed... subscribe to Premium to read more.
Long-term Liabilities Financials
SHOT's debt relative to shareholder... subscribe to Premium to read more.
Shrinking Debt Financials
SHOT's debt to equity ratio... subscribe to Premium to read more.
Healthy Debt to Equity Financials
Cash flow
Operating
-$848.0k
Investing
-$252.5k
Financing
$787.6k
SHOT's cash and short-term investments... subscribe to Premium to read more.
Debt Coverage Financials
SHOT vs Beverage Stocks
Safety Shot Stock FAQ
Company
AboutNewsBlogStock Investing FAQPlansPrivacy PolicyTerms of ServiceCancellation & RefundsPerformanceHelp GuidesContactTwitterYouTubeNewsletterWallStreetZen does not provide financial advice and does not issue recommendations or offers to buy stock or sell any security.
Information is provided 'as-is' and solely for informational purposes and is not advice. WallStreetZen does not bear any responsibility for any losses or damage that may occur as a result of reliance on this data.
Information is provided 'as-is' and solely for informational purposes and is not advice. WallStreetZen does not bear any responsibility for any losses or damage that may occur as a result of reliance on this data.